Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo

Hung, Kuan‐Yu; Shyu, Ren-Shi; Tsai, Chien-Chen; Lee, Po‐Huang; Tsai, Tun-Jun; Hsieh, Bor‐Shen

doi:10.1046/j.1523-1755.2001.00749.x

Cited by 25 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TGF-β production and the activated signal pathway are important mediators leading to PF [13,14]. In addition, TGF-β is associated with PF in rat models [15,16]. These results further support the central role of TGF-β in PF.…”

Section: Introductionmentioning

confidence: 67%

Tamoxifen Downregulates Connective Tissue Growth Factor to Ameliorate Peritoneal Fibrosis

Huang

Yen

et al. 2011

Blood Purif

Self Cite

View full text Add to dashboard Cite

Peritoneal fibrosis (PF), including simple sclerosis and encapsulating peritoneal sclerosis (EPS), is a serious complication in patients on long-term peritoneal dialysis. Tamoxifen has successfully been used in treating EPS; however, the mechanism of tamoxifen in treating EPS fibrosis disorders remains unclear. This study demonstrates a possible antifibrotic mechanism of tamoxifen. A bleach-induced PF rat model was applied as the in vivo treatment target. Tamoxifen was intraperitoneally injected daily to treat PF. The PF scores and thickness of the submesothelial zone over the liver surface were measured as indicators for the severity of PF. Human peritoneal mesothelial cells (HPMC) were used as an in vitro model to test the antifibrotic effect of tamoxifen. Gene expressions of transforming growth factors-β (TGF-β), connective tissue growth factor (CTGF) and collagen were investigated using quantitative polymerase chain reactions. In HPMC, tamoxifen showed paradoxical effects between collagen I and TGF-β. Tamoxifen also inhibited TGF-β-induced collagen and CTGF. The possible antifibrotic effect of tamoxifen is through inhibiting CTGF to block collagen synthesis, although it enhances TGF-β which increases fibrosis. These results provide a possible molecular mechanism for tamoxifen.

show abstract

Section: Introductionmentioning

confidence: 67%

Tamoxifen Downregulates Connective Tissue Growth Factor to Ameliorate Peritoneal Fibrosis

Huang

Yen

et al. 2011

Blood Purif

Self Cite

View full text Add to dashboard Cite

show abstract

“…5,7,8,[15][16][17]27,28 Previous studies have found no significant association between peritoneal wall thickness by US and peritonitis frequency. 15,[17][18][19] On the contrary, however, we found for the first time, a positive correlation between peritoneal thickness and episode of peritonitis (R 2 ¼ 0.933, Figure 4C).…”

Section: Discussionmentioning

confidence: 99%

“…Although the definitive diagnosis of PFS can be made by peritoneal biopsy, ethical issues, difficulty of the process and insufficient knowledge of PFS are the major obstacles for routine clinical application of peritoneal membrane biopsy. 3,[5][6][7][8][9][10] Measurement of cytokines levels which are responsible in PFS progression can be an alternative diagnostic tool. 3 However, there is no consensus on the time and the frequency of cytokines monitoring in the diagnosis of PFS.…”

Section: Introductionmentioning

confidence: 99%

The importance of ultrasonographic measurement of peritoneal wall thickness in pediatric chronic peritoneal dialysis patients

et al. 2015

View full text Add to dashboard Cite

Loss of peritoneal function due to peritoneal fibrosing syndrome (PFS) is a major factor leading to treatment failure in chronic peritoneal dialysis (PD) patients. Although the precise biologic mechanisms responsible for these changes have not been defined, the general assumption is that alterations in peritoneal function are related to structural changes in the peritoneal membrane. Studies of the peritoneal membrane by non-invasive ultrasonography (US) in chronic PD patients are limited. The aim of the present study is to assess the relationship between functional parameters of peritoneum and peritoneal thickness measured by US in children treated by chronic PD. We recruited two groups of patients: 23 subjects (13 females, 10 males) on chronic PD (patient group) and 26 (7 females, 19 males) on predialysis out-patient follow-up (creatinine clearance: 20-60 mL/min/1.73 m 2 ) (control group). Age, sex, weight, height, body mass index (BMI), chronic PD duration, episodes of peritonitis and the results of peritoneal equilibration test (PET) were recorded. Hemoglobin (Hb), blood pressure (BP), left ventricular mass index (LVMI) and renal osteodystrophy (ROD) parameters were also obtained. The thickness of the parietal peritoneum was measured by trans-abdominal US in all children. Statistical analyses were performed by using Student's t and Pearson's correlation tests. Mean peritoneal thickness in chronic PD patients (1028.26 ± 157.26 mm) was significantly higher than control patients (786.52 ± 132.33 (R 2 ¼ 0.81, p50.05). No correlation was found between peritoneal thickness and Hb, BP, LVMI and ROD parameters. In conclusion, ultrasonographic measurement of peritoneal membrane thickness is a simple and non-invasive method in chronic PD children. This diagnostic tool likely enables to assess peritoneal structure and function in these patients.

show abstract

“…Next, the cells along with the supernatants were collected after scraping, and cAMP levels were analyzed using an ELISA kit. 11 In endothelial cells grown in parallel and treated similarly, the monolayers were inspected microscopically for intactness, the protein content was measured, and the data were normalized to protein content.…”

Section: Camp Synthesismentioning

confidence: 99%

A _2B Adenosine Receptors Stimulate Growth of Porcine and Rat Arterial Endothelial Cells

Dubey¹,

Gillespie²,

Jackson³

2002

Hypertension

View full text Add to dashboard Cite

Abstract-The goal of this study was to determine which adenosine receptor subtype mediates growth stimulation by adenosine in arterial endothelial cells. In porcine coronary artery and rat aortic endothelial cells, 2-chloroadenosine (Cl-Ad), a metabolically stable analog of adenosine, stimulated DNA synthesis ( 3 H-thymidine incorporation), cellular proliferation (cell number), collagen synthesis ( 3 H-proline incorporation), and cell migration. The growth effects of adenosine and Cl-Ad were mimicked by the adenosine receptor agonist 5Ј-N-methylcarboxamidoadenosine but not by the adenosine receptor agonists N 6 -cyclopentyladenosine, 4-aminobenzyl-5Ј-N-methylcarboxamidoadenosine or CGS21680, an agonist profile consistent with an A 2B receptor-mediated effect. The adenosine receptor antagonists KF17837 and 1,3-dipropyl-8-p-sulfophenylxanthine but not 8-cyclopentyl-1,3-dipropylxanthine blocked the growthstimulatory effects of Cl-Ad and 5Ј-N-methylcarboxamidoadenosine, an antagonist profile consistent with an A 2 receptor-mediated action. Treatment of endothelial cells with erythro-9-(2-hydroxy-3-nonyl) adenine plus iodotubericidin (inhibitors of adenosine deaminase and adenosine kinase, respectively) induced endothelial cell growth, and these effects were blocked by 1,3-dipropyl-8-p-sulfophenylxanthine and KF17837 but not 8-cyclopentyl-1,3-dipropylxanthine, suggesting that endothelial cell-derived adenosine induces growth via A 2 receptors. The growthstimulatory effects of Cl-Ad, 5Ј-N-methylcarboxamidoadenosine, and erythro-9-(2-hydroxy-3-nonyl) adenine plus iodotubericidin were abolished by antisense but not scrambled or sense oligonucleotides to the A 2B receptor. Our findings strongly support the hypothesis that adenosine induces endothelial cell growth by activating A 2B receptors. Thus, A 2B receptors may play a critical role in regulating vascular remodeling associated with endothelial cell proliferation in angiogenesis, collateral vessel development, and recovery after vascular injury. Pharmacological or molecular biological activation of A 2B receptors may be useful in modulating vascular remodeling.

show abstract

Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo

Abstract: This study suggests that dipyridamole may have therapeutic potential in treating peritoneal fibrosis.

Cited by 25 publications

References 17 publications

Tamoxifen Downregulates Connective Tissue Growth Factor to Ameliorate Peritoneal Fibrosis

Tamoxifen Downregulates Connective Tissue Growth Factor to Ameliorate Peritoneal Fibrosis

The importance of ultrasonographic measurement of peritoneal wall thickness in pediatric chronic peritoneal dialysis patients

A _2B Adenosine Receptors Stimulate Growth of Porcine and Rat Arterial Endothelial Cells

Contact Info

Product

Resources

About

Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo

Abstract: This study suggests that dipyridamole may have therapeutic potential in treating peritoneal fibrosis.

Cited by 25 publications

References 17 publications

Tamoxifen Downregulates Connective Tissue Growth Factor to Ameliorate Peritoneal Fibrosis

Tamoxifen Downregulates Connective Tissue Growth Factor to Ameliorate Peritoneal Fibrosis

The importance of ultrasonographic measurement of peritoneal wall thickness in pediatric chronic peritoneal dialysis patients

A 2B Adenosine Receptors Stimulate Growth of Porcine and Rat Arterial Endothelial Cells

Contact Info

Product

Resources

About

A _2B Adenosine Receptors Stimulate Growth of Porcine and Rat Arterial Endothelial Cells